FDA extends review date for Celgene cancer drug

CHICAGO, Oct 3 (Reuters) – Celgene Corp. (CELG.O: Quote, Profile, Research) on Monday said U.S. regulators notified the company late Friday that the date for reviewing an application for its cancer drug Revlimid has been extended by three months, to Jan. 7.

Celgene said it expects to submit in November its application for Revlimid to treat previously treated patients with relapsed multiple myeloma.

Last week, Celgene said it expected a suspended trial of the drug to resume within weeks, after the trial design is changed to ensure all patients receive aspirin to reduce the chance of developing blood clots.